Key Takeaways:
Senti Biosciences Inc. (Nasdaq: SNTI) secured up to $40 million in new financing and received positive feedback from U.S. regulators for its lead cancer therapy, SENTI-202, paving the way for a pivotal trial in patients with acute myeloid leukemia. The developments address key clinical and financial hurdles for the company.
“This positive FDA RMAT meeting marks a transformational moment for Senti Bio and significantly advances our path toward potential registration of SENTI-202,” Timothy Lu, Chief Executive Officer and Co-Founder of Senti Bio, said in a statement. “This news, combined with the compelling clinical responses observed to date that led to refinements in our donor selection strategy, positions us to advance SENTI-202 toward a potential registrational study.”
The regulatory update follows a successful Type B meeting with the Food and Drug Administration, which supports a single-arm, multi-center pivotal trial for SENTI-202 in relapsed/refractory AML. The decision was based on Phase 1 data where the therapy demonstrated durable responses. Senti also announced the discovery of a "Donor X" phenotype that correlates with higher efficacy. Patients receiving cells from Donor X donors achieved a 50% composite complete remission rate, compared to just 12.5% for patients receiving cells from other donors.
The dual catalysts of regulatory clarity and fresh capital address two major risks for the clinical-stage biotech, extending its operational runway and de-risking the development path for its lead asset. Senti's stock rose 3.84% to $1.00 on the news. The financing is crucial as the company's cash and cash equivalents had declined to $8.9 million as of March 31, from $16.4 million at the end of 2025.
SENTI-202 is an allogeneic, or "off-the-shelf," CAR-NK cell therapy. It uses the company's Gene Circuit platform with "Logic Gates" designed to target CD33 and/or FLT3, antigens found on leukemia cells, while sparing healthy cells. This approach aims to widen the therapeutic window and reduce toxicity.
The discovery of the Donor X attribute, which Senti says is found in about 50% of adult donors, is a significant step toward optimizing the therapy's efficacy. The company confirmed that all future manufacturing of SENTI-202, including for the pivotal trial, will use cells sourced from donors with this attribute.
"The excellent clinical activity observed thus far, including MRD-negative durable complete remissions alongside a favorable safety profile, gives us confidence as we transition toward later-stage development," said Kanya Rajangam, Senti Bio's Chief Medical Officer. The longest remission observed in the Phase 1 study has lasted over 21 months.
The strategic financing was made with an affiliate of Celadon Partners SPV 24. It includes an initial $10 million tranche of senior secured convertible notes, expected to close in May, with an option for an additional $30 million.
The funding arrives as Senti Bio has worked to streamline its operations. The company reported a first-quarter net loss of $4.2 million, or $0.14 per share, a significant improvement from a net loss of $14.1 million, or $1.41 per share, in the same period a year ago. The reduced loss was aided by a $6.9 million one-time gain from a lease modification. Operating cash burn for the quarter was nearly halved to $7.5 million from $14.1 million year-over-year.
This article is for informational purposes only and does not constitute investment advice.
